SRPT
Sarepta Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +3.2% · netto nieuwe posities -5.9% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 19.39K | $353,037 | n/a | −2 |
| Q2 2026 | 109 | +2 | 83.38M | $1.50B | +13 | −12 |
| Q1 2026 | 111 | +1 | 76.41M | $1.66B | +6 | −6 |
| Q4 2025 | 110 | +2 | 75.97M | $1.63B | +3 | n/a |
| Q3 2025 | 17 | 0 | 44.07M | $848.49M | +2 | −3 |
| Q2 2025 | 15 | -1 | 40.14M | $686.46M | +1 | −2 |
| Q1 2025 | 13 | -1 | 11.03M | $703.96M | +1 | −2 |
| Q4 2024 | 14 | -1 | 10.27M | $1.25B | +2 | −3 |
| Q3 2024 | 14 | +1 | 7.65M | $955.24M | +1 | n/a |
| Q2 2024 | 13 | n/a | 7.85M | $1.24B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 13.20M | +8.9% | $254.36M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (passief) | 10.82M | +18.1% | $208.45M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passief) | 5.30M | +13.0% | $102.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 2.65M | +324.4% | $51.07M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 2.14M | -1.1% | $41.19M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 2.01M | -55.2% | $38.68M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 1.95M | n/a | $37.54M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 8 | Geode Capital Management ✦ (passief) | 1.72M | -8.3% | $33.17M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 1.41M | +1015.8% | $26.40M | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 10 | JPMorgan Chase ✦ | 1.34M | n/a | $25.80M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 11 | Citadel Advisors ✦ | 512.48K | +69.6% | $9.88M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Bridgewater Associates ✦ | 352.27K | Nieuw | $6.79M | 0.0% | New | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 284.21K | -73.2% | $5.48M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Goldman Sachs Group ✦ | 177.15K | n/a | $3.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | Marshall Wace ✦ | 105.11K | Nieuw | $2.03M | 0.0% | New | 1 | SEC ↗ ×3 |
| 16 | T. Rowe Price ✦ | 90.03K | +17.2% | $1.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Fidelity (FMR) ✦ | 14.37K | +75.4% | $276,993 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $6.79M | 0.0% |
| Marshall Wace | $2.03M | 0.0% |
Verlaten
| Wellington Management | $43.27M | was 0.0% |
| Norges Bank | $15.62M | was 0.0% |
| Fisher Asset Management | $220,761 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 339 houders, 102.41M aandelen, $2.16B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.